微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 73.61% | 1.42% | -2.25% | 28/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 75.31% | 2.71% | 0.61% | 26/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 74.85% | 4.53% | 3.76% | 28/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 72.13% | -3.73% | -0.61% | 30/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 72.58% | -3.73% | -1.01% | 32/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 73.32% | -2.54% | 2.39% | 28/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 71.6% | -1.85% | -4.44% | 28/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 74.93% | 0.89% | -0.61% | 25/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 75.39% | 0.39% | 0.21% | 24/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 75.23% | 0.75% | 3.12% | 25/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 72.95% | -0.2% | -1.77% | 26/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 74.27% | -2.26% | -1.1% | 30/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 75.09% | -0.18% | 0.56% | 30/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 74.67% | -1.01% | 2.16% | 30/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 73.1% | -1.93% | -3.8% | 31/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 75.98% | -0.96% | 1.01% | 32/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 75.22% | -1.48% | -0.29% | 33/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 75.44% | -0.28% | 1.21% | 31/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 74.54% | -0.22% | -2.84% | 33/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 76.72% | -3.89% | 0.48% | 32/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 76.35% | -6.97% | 0.93% | 24/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 75.65% | -7.07% | 1.27% | 29/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 74.7% | -6.14% | -6.42% | 24/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 79.83% | -3.6% | -2.73% | 23/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 82.07% | -3.3% | 0.81% | 17/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 81.41% | -4.27% | 2.29% | 14/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 79.59% | -4.43% | -3.89% | 16/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 82.81% | -1.07% | -2.43% | 14/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 84.87% | 0.09% | -0.2% | 8/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 85.04% | 4.07% | 2.11% | 11/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 83.28% | 4.06% | -0.51% | 10/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 83.7% | 6.36% | -1.29% | 17/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 84.8% | 9.09% | 3.77% | 9/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 81.72% | 10.75% | 2.11% | 12/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 80.03% | 11.95% | 1.69% | 13/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 78.7% | 14.49% | 1.25% | 18/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 77.73% | 14.03% | 5.35% | 9/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 73.78% | 9.36% | 3.21% | 12/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 71.49% | 9.15% | 4% | 14/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 68.74% | 34.31% | 0.84% | 19/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 68.17% | 32.6% | 1.04% | 14/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 67.47% | 29.51% | 3.01% | 17/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 65.49% | 18.14% | 27.97% | 14/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |